Pharmaceutical Executive - PharmExec
网页Pharmaceutical Executive-03-01-2022. ... Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Pharmaceutical Executive
网页Bimzelx is the first approved medication for active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis that selectively inhibits IL-17A and IL-17F, both of which are key cytokines that drive inflammatory processes. Fidelis Care and Centene Foundation Provide $1 Million Grant to Jed Foundation.
Executive Profiles - PharmExec
网页2024年5月10日 — Elaine Quilici. October 13th 2023. Stephen Rivera, vice president, global technical accounting advisory services and policy, Johnson & Johnson, capitalizes on his lively personality—and a courageous career journey—to bring people together to shape the future of biopharma.
2022 Pharm Exec Top 50 Companies
网页2022年6月9日 — If 2020 was the “Year of COVID,” as we referred to it in our Pharm Exec 50 feature last year—reflecting on the pandemic’s scope and disruption on all facets of life—then 2021 was surely the year of COVID vaccines and treatments. And, through the prism of our latest rankings of the top 50 global biopharma players based on prescription …
Out-licensing Deals Between Chinese Pharma and Global
网页2024年1月19日 — In 2023, China engaged in innovative drug out-licensing transactions for more than 10 small molecule drugs that target various proteins, such as TLR8, EZH2, TYK2/JAK1, HER2, PARP1, PI3K, ROS1/NTRK, KRASG12D, GLP-1, and DPP1. These small molecule drugs include several new medications that work through a "synthetic …
2024 Pharm Exec Top 50 Companies
网页2024年6月14日 — Dethroning Pfizer at the top of our Pharma 50 is Johnson & Johnson ($53.46 billion in Rx sales), up 6.5% and jumping from third, driven by its “fairly diversified portfolio,” notes Verdin. J&J boasts a pair of treatments among the industry’s top-10 sellers (see chart above), including its longtime immunosuppressant, Stelara, which went ...
Cold Chain: Delivering Innovative Specialty Pharmaceutical
网页2021年10月11日 — Global spending on biopharma cold chain logistics has climbed steadily since 2018 2 and is expected to grow another 25 percent over the next three years, reaching $21.3 billion in 2024. In 2020, about $5 billion—nearly 30 percent of the $17.5 billion spent on pharmaceutical cold chain—went toward packaging costs, as well as tracking ...
2021 Pharm Exec Top 50 Companies
网页2021年6月9日 — Manning the last two positions in the Pharma 50 top 10 are once again GlaxoSmithKline and Takeda. GSK, still planning to split the organization into two next year, recently announced plans to sell its complete stake in respiratory drug partner Innoviva (a royalty management company) for about $392 million.
Supply Chain - PharmExec
网页2023年12月11日 — The 2013 Drug Supply Chain Security Act (DSCSA) established a framework for exchanging data when products are transacted throughout the US pharma supply chain. Its goal, by November 2023, is to enable unit-level traceability in a secure, interoperable manner. HDA’s Chip Davis talks about how pharma manufacturers must …
21st Annual Industry Audit: Pharma Performance Check - PharmExec
网页2022年9月9日 — Welcome to Pharm Exec ’s 21st annual Pharmaceutical Industry Audit. We present a unique financial performance analysis of the top 18 publicly traded biopharmaceutical companies based on 2021 sales revenue and other financial metrics. We focus on a number of financial performance metrics, especially critical metrics such as …